Trial Profile
A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 03 Jan 2024 Results of pooled analysis from CO.17 and CO.20 investigating transverse colon primary tumor location as a biomarker in mCRC, published in the Clinical Cancer Research
- 21 Jan 2023 Results of pooled analysis of two studies (CO.17 and CO.20) assessing the predictive and prognostic features of transverse colon primary location, presented at the 2023 Gastrointestinal Cancers Symposium.
- 20 Jan 2018 Results assessing the association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated patients (n=592) presented at the 2018 Gastrointestinal Cancers Symposium